Health Care • Biotechnology: Pharmaceutical Preparations
$253.00 ▲ +3.45
(+1.38%)
MKT CAP: $16.67B • VOL: 491.5K
52W L $188 52W H $282
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$213
MEDIAN
$283
MEAN
$288
HIGH
$344
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ASND TAPE
ASND // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $306.13 | $290.95 | 2025-02-14 | $230.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $318.78 | $298.54 | 2025-02-06 | $237.82 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $288.42 | $278.30 | 2025-01-29 | $242.88 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $258.06 | — | 2025-01-17 | $247.94 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $222.64 | $240.35 | 2025-01-09 | $225.17 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $301.07 | $263.12 | 2024-12-18 | $220.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $245.41 | $255.53 | 2024-12-04 | $235.29 | -4.3% | 48% | C |